VIMIAN logo

Vimian Group AB (publ) Stock Price

OM:VIMIAN Community·SEK 16.2b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

VIMIAN Share Price Performance

SEK 30.65
-8.11 (-20.92%)
SEK 34.98
Fair Value
SEK 30.65
-8.11 (-20.92%)
12.4% undervalued intrinsic discount
SEK 34.98
Fair Value
Price SEK 30.65
AnalystConsensusTarget SEK 34.98
AnalystHighTarget SEK 41.10
AnalystLowTarget SEK 24.91

VIMIAN Community Narratives

·
Fair Value SEK 34.98 12.4% undervalued intrinsic discount

Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value SEK 41.1 25.4% undervalued intrinsic discount

Emerging Pet Trends And Digital Diagnostics Will Redefine Animal Healthcare

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value SEK 24.91 23.1% overvalued intrinsic discount

Rising Interest Rates And Tariffs Will Weaken US MedTech Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
SEK 24.91
23.1% overvalued intrinsic discount
Revenue
9.33% p.a.
Profit Margin
15.06%
Future PE
18.02x
Price in 2029
SEK 29.88

Trending Discussion

Updated Narratives

VIMIAN logo

VIMIAN: Margin Execution And Governance Changes Will Support Future Upside Potential

Fair Value: SEK 34.98 12.4% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
VIMIAN logo

VIMIAN: Higher Discount Rate Will Constrain Future Upside Potential

Fair Value: SEK 24.91 23.1% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
VIMIAN logo

VIMIAN: Reset Expectations Will Highlight Execution Under New CEO Appointment

Fair Value: SEK 41.1 25.4% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Reasonable growth potential with proven track record.

0 Risks
3 Rewards

Vimian Group AB (publ) Key Details

€433.6m

Revenue

€134.4m

Cost of Revenue

€299.2m

Gross Profit

€262.4m

Other Expenses

€36.8m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 17, 2026
0.07
69.00%
8.49%
31.5%
View Full Analysis

About VIMIAN

Founded
2020
Employees
1300
CEO
Alireza Tajbakhsh
WebsiteView website
vimian.com

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, education, and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and surgical and dental products to veterinary clinics and universities, including dentistry and companion animal orthopedics under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.

Recent VIMIAN News & Updates

Narrative Update May 06

VIMIAN: Margin Execution And Governance Changes Will Support Future Upside Potential

Analysts now see fair value for Vimian Group at about SEK 35, up from roughly SEK 34, even though the latest Street research includes a reduced price target to SEK 25 from SEK 27. This reflects updated views on revenue growth, margins, the appropriate discount rate and future P/E assumptions.

Recent updates

No updates